Editas Medicine Past Earnings Performance
Past criteria checks 0/6
Editas Medicine's earnings have been declining at an average annual rate of -14%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 0.4% per year.
Key information
-14.0%
Earnings growth rate
-4.7%
EPS growth rate
Biotechs Industry Growth | 11.5% |
Revenue growth rate | 0.4% |
Return on equity | -43.9% |
Net Margin | -196.1% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Editas Medicine makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 78 | -153 | 70 | 0 |
30 Sep 23 | 25 | -195 | 73 | 0 |
30 Jun 23 | 19 | -206 | 74 | 0 |
31 Mar 23 | 23 | -219 | 74 | 1 |
31 Dec 22 | 20 | -220 | 71 | 0 |
30 Sep 22 | 26 | -201 | 69 | 0 |
30 Jun 22 | 32 | -184 | 69 | 0 |
31 Mar 22 | 26 | -186 | 74 | 34 |
31 Dec 21 | 26 | -193 | 76 | 0 |
30 Sep 21 | 24 | -214 | 75 | 0 |
30 Jun 21 | 81 | -167 | 79 | 0 |
31 Mar 21 | 92 | -135 | 71 | 0 |
31 Dec 20 | 91 | -116 | 68 | 0 |
30 Sep 20 | 92 | -91 | 69 | 0 |
30 Jun 20 | 33 | -132 | 65 | 0 |
31 Mar 20 | 24 | -142 | 65 | 0 |
31 Dec 19 | 21 | -134 | 65 | 0 |
30 Sep 19 | 14 | -121 | 61 | 0 |
30 Jun 19 | 25 | -103 | 58 | 0 |
31 Mar 19 | 30 | -108 | 58 | 0 |
31 Dec 18 | 32 | -110 | 55 | 0 |
30 Sep 18 | 29 | -121 | 56 | 0 |
30 Jun 18 | 21 | -132 | 55 | 0 |
31 Mar 18 | 17 | -120 | 52 | 0 |
31 Dec 17 | 14 | -120 | 51 | 0 |
30 Sep 17 | 11 | -124 | 50 | 0 |
30 Jun 17 | 6 | -118 | 49 | 0 |
31 Mar 17 | 6 | -111 | 49 | 0 |
31 Dec 16 | 6 | -97 | 46 | 0 |
30 Sep 16 | 6 | -71 | 41 | 0 |
30 Jun 16 | 6 | -57 | 33 | 0 |
31 Mar 16 | 2 | -86 | 25 | 0 |
31 Dec 15 | 2 | -73 | 18 | 0 |
30 Sep 15 | 1 | -66 | 14 | 0 |
30 Jun 15 | 0 | -62 | 11 | 0 |
31 Mar 15 | 0 | -17 | 9 | 0 |
31 Dec 14 | 0 | -14 | 8 | 0 |
Quality Earnings: 0IFK is currently unprofitable.
Growing Profit Margin: 0IFK is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0IFK is unprofitable, and losses have increased over the past 5 years at a rate of 14% per year.
Accelerating Growth: Unable to compare 0IFK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0IFK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: 0IFK has a negative Return on Equity (-43.89%), as it is currently unprofitable.